Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark Pharmaceuticals receives tentative ANDA approval for Clindamycin Phosphate Foam, 1%

June 20, 2019

Glenmark Pharmaceuticals receives ANDA approval for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg

May 27, 2019

Glenmark Pharmaceuticals receives ANDA approval for Solifenacin Succinate Tablets, 5 mg and 10 mg

May 21, 2019

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%

May 15, 2019

Glenmark Pharmaceuticals receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg

May 14, 2019

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

June 20, 2019
Glenmark Pharmaceuticals receives tentative ANDA approval for Clindamycin Phosphate Foam, 1%

May 27, 2019
Glenmark Pharmaceuticals receives ANDA approval for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg

May 21, 2019
Glenmark Pharmaceuticals receives ANDA approval for Solifenacin Succinate Tablets, 5 mg and 10 mg

May 15, 2019
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%

May 14, 2019
Glenmark Pharmaceuticals receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE